FDA Approves Revumenib for Relapsed or Refractory Acute Leukaemia with a KMT2A Translocation By Ogkologos - December 10, 2024 604 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AUGMENT-101 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Enzalutamide Plus ADT Significantly Prolongs Survival in Patients with Metastatic Hormone-Sensitive... April 25, 2022 10 Ways the Inflation Reduction Act will Impact Cancer Care August 18, 2022 FDA Approves Melphalan As a Liver-Directed Treatment for Uveal Melanoma September 8, 2023 A cut above: Making drug discovery more efficient using CRISPR August 16, 2022 Load more HOT NEWS Hospital Lockdown Prevents Breast Cancer Patient from Receiving Treatment for 3... What’s Your Mantra? CAR T-Cell Therapy Approved by FDA for Mantle Cell Lymphoma Cancer Survivor with Strong Family History Was Denied Regular Screening Because...
